Jaguar Health Inc is a biopharmaceutical company focused on developing and commercializing innovative therapies for gastrointestinal diseases, primarily for patients with chronic, debilitating conditions
The company emphasizes its commitment to using natural products derived from plants to create treatments, with a particular focus on improving the quality of life for those suffering from gastrointestinal disorders. By harnessing the power of botanical medicines, Jaguar Health aims to address both the symptoms and the underlying causes of these conditions, supporting patient wellness and enhancing standard care practices.
Jaguar Health shares are falling Tuesday after the company announced its phase 3 OnTarget trial did not meet its primary endpoint. Here's a look at the details:
Jaguar Health shares are falling after the stock effected a reverse split at an exchange ratio of 1-for-60 Thursday, in order to support the company's compliance with Nasdaq listing standards.
Jaguar Health shares are falling Monday after the company announced a 1-for-60 reverse stock split. The company will effect a reverse stock split at an exchange ratio of 1-for-60, on Thursday, in order to support the company's compliance with Nasdaq's listing standards.
